382 related articles for article (PubMed ID: 12545140)
1. Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection.
Csajka C; Marzolini C; Fattinger K; Décosterd LA; Fellay J; Telenti A; Biollaz J; Buclin T
Clin Pharmacol Ther; 2003 Jan; 73(1):20-30. PubMed ID: 12545140
[TBL] [Abstract][Full Text] [Related]
2. Population pharmacokinetics of efavirenz in an unselected cohort of HIV-1-infected individuals.
Kappelhoff BS; Huitema AD; Yalvaç Z; Prins JM; Mulder JW; Meenhorst PL; Beijnen JH
Clin Pharmacokinet; 2005; 44(8):849-61. PubMed ID: 16029069
[TBL] [Abstract][Full Text] [Related]
3. Nevirapine and efavirenz pharmacokinetics and covariate analysis in the 2NN study.
Kappelhoff BS; van Leth F; MacGregor TR; Lange J; Beijnen JH; Huitema AD;
Antivir Ther; 2005; 10(1):145-55. PubMed ID: 15751772
[TBL] [Abstract][Full Text] [Related]
4. Population pharmacokinetics of indinavir in patients infected with human immunodeficiency virus.
Csajka C; Marzolini C; Fattinger K; Décosterd LA; Telenti A; Biollaz J; Buclin T
Antimicrob Agents Chemother; 2004 Sep; 48(9):3226-32. PubMed ID: 15328077
[TBL] [Abstract][Full Text] [Related]
5. Intra-individual variability in efavirenz plasma concentrations supports therapeutic drug monitoring based on quarterly sampling in the first year of therapy.
Pereira SA; Branco T; Caixas U; Côrte-Real RM; Germano I; Lampreia F; Monteiro EC
Ther Drug Monit; 2008 Feb; 30(1):60-6. PubMed ID: 18223464
[TBL] [Abstract][Full Text] [Related]
6. The steady-state pharmacokinetics of efavirenz and nevirapine when used in combination in human immunodeficiency virus type 1-infected persons.
Veldkamp AI; Harris M; Montaner JS; Moyle G; Gazzard B; Youle M; Johnson M; Kwakkelstein MO; Carlier H; van Leeuwen R; Beijnen JH; Lange JM; Reiss P; Hoetelmans RM
J Infect Dis; 2001 Jul; 184(1):37-42. PubMed ID: 11398107
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetics of atazanavir in patients with human immunodeficiency virus infection.
Colombo S; Buclin T; Cavassini M; Décosterd LA; Telenti A; Biollaz J; Csajka C
Antimicrob Agents Chemother; 2006 Nov; 50(11):3801-8. PubMed ID: 16940065
[TBL] [Abstract][Full Text] [Related]
8. Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring.
Gutiérrez F; Navarro A; Padilla S; Antón R; Masiá M; Borrás J; Martín-Hidalgo A
Clin Infect Dis; 2005 Dec; 41(11):1648-53. PubMed ID: 16267739
[TBL] [Abstract][Full Text] [Related]
9. Intracellular and plasma efavirenz concentrations in HIV-infected patients switching from successful protease inhibitor-based highly active antiretroviral therapy (HAART) to efavirenz-based HAART (SUSTIPHAR Study).
Djabarouti S; Breilh D; Pellegrin I; Lavit M; Camou F; Caubet O; Fleury H; Saux MC; Pellegrin JL
J Antimicrob Chemother; 2006 Nov; 58(5):1090-3. PubMed ID: 16921181
[TBL] [Abstract][Full Text] [Related]
10. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients.
Marzolini C; Telenti A; Decosterd LA; Greub G; Biollaz J; Buclin T
AIDS; 2001 Jan; 15(1):71-5. PubMed ID: 11192870
[TBL] [Abstract][Full Text] [Related]
11. A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study.
Manosuthi W; Sungkanuparph S; Tantanathip P; Lueangniyomkul A; Mankatitham W; Prasithsirskul W; Burapatarawong S; Thongyen S; Likanonsakul S; Thawornwa U; Prommool V; Ruxrungtham K;
Clin Infect Dis; 2009 Jun; 48(12):1752-9. PubMed ID: 19438397
[TBL] [Abstract][Full Text] [Related]
12. Efavirenz plasma levels for the prediction of treatment failure in heavily pretreated HIV-1 infected patients.
Langmann P; Weissbrich B; Desch S; Väth T; Schirmer D; Zilly M; Klinker H
Eur J Med Res; 2002 Jul; 7(7):309-14. PubMed ID: 12176680
[TBL] [Abstract][Full Text] [Related]
13. Efavirenz and nevirapine in HIV-1 infection : is there a role for clinical pharmacokinetic monitoring?
Dahri K; Ensom MH
Clin Pharmacokinet; 2007; 46(2):109-32. PubMed ID: 17253884
[TBL] [Abstract][Full Text] [Related]
14. Efavirenz, tenofovir and emtricitabine combined with first-line tuberculosis treatment in tuberculosis-HIV-coinfected Tanzanian patients: a pharmacokinetic and safety study.
Semvua HH; Mtabho CM; Fillekes Q; van den Boogaard J; Kisonga RM; Mleoh L; Ndaro A; Kisanga ER; van der Ven A; Aarnoutse RE; Kibiki GS; Boeree MJ; Burger DM
Antivir Ther; 2013; 18(1):105-13. PubMed ID: 23043067
[TBL] [Abstract][Full Text] [Related]
15. [Evidence-based therapeutic drug monitoring for efavirenz].
Solas C; Gagnieu MC;
Therapie; 2011; 66(3):197-205. PubMed ID: 21819803
[TBL] [Abstract][Full Text] [Related]
16. Efavirenz trough levels are not associated with virological failure throughout therapy with 800 mg daily and a rifampicin-containing antituberculosis regimen.
Lopez-Cortes LF; Ruiz-Valderas R; Ruiz-Morales J; Leon E; de Campos AV; Marin-Niebla A; Marquez-Solero M; Lozano F; Valiente R
J Antimicrob Chemother; 2006 Nov; 58(5):1017-23. PubMed ID: 16956905
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of the nonnucleoside reverse transcriptase inhibitor efavirenz among HIV-infected Ugandans.
Nanzigu S; Eriksen J; Makumbi F; Lanke S; Mahindi M; Kiguba R; Beck O; Ma Q; Morse GD; Gustafsson LL; Waako P
HIV Med; 2012 Apr; 13(4):193-201. PubMed ID: 22107359
[TBL] [Abstract][Full Text] [Related]
18. Plasma concentrations of efavirenz are associated with body weight in HIV-positive individuals.
Poeta J; Linden R; Antunes MV; Real L; Menezes AM; Ribeiro JP; Sprinz E
J Antimicrob Chemother; 2011 Nov; 66(11):2601-4. PubMed ID: 21890538
[TBL] [Abstract][Full Text] [Related]
19. Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and CYP2B6 polymorphism.
Burger D; van der Heiden I; la Porte C; van der Ende M; Groeneveld P; Richter C; Koopmans P; Kroon F; Sprenger H; Lindemans J; Schenk P; van Schaik R
Br J Clin Pharmacol; 2006 Feb; 61(2):148-54. PubMed ID: 16433869
[TBL] [Abstract][Full Text] [Related]
20. Population pharmacokinetic meta-analysis with efavirenz.
Barrett JS; Joshi AS; Chai M; Ludden TM; Fiske WD; Pieniaszek HJ
Int J Clin Pharmacol Ther; 2002 Nov; 40(11):507-19. PubMed ID: 12698988
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
